» Articles » PMID: 1504712

Enteral Absorption of Octreotide

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1992 Apr 1
PMID 1504712
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

1. The somatostatin octapeptide-analogue, octreotide, is absorbed as intact peptide from the gastrointestinal (GI) tract. 2. In situ absorption experiments in rats confirmed our recent intubation studies in human volunteers demonstrating that the peptide has preferential absorption sites in the small intestine. Absorption of octreotide was higher in the jejunum than in the duodenum or the ileum. 3. Experiments with bile-duct cannulated rats demonstrated that the absorption of octreotide decreased in the presence of bile, reflecting a negative influence of biliary components on the absorption of the peptide. 4. Uptake experiments using rat jejunal brush border membranes were performed to analyse the absorption mechanisms. The transport of octreotide into jejunal brush border membranes was significantly higher than the uptake into membrane vesicles isolated from rat ileum. When initial uptake (0-15s) rates into the membrane vesicles were calculated as a function of the peptide concentration, a saturable component could be observed, indicative of transport mechanisms different from simple diffusion.

Citing Articles

On the Utility of Chemical Strategies to Improve Peptide Gut Stability.

Kremsmayr T, Aljnabi A, Blanco-Canosa J, Tran H, Braga Emidio N, Muttenthaler M J Med Chem. 2022; 65(8):6191-6206.

PMID: 35420805 PMC: 9059125. DOI: 10.1021/acs.jmedchem.2c00094.


Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide.

Li P, Ford L, Haque S, McInerney M, Williams H, Scammells P Pharm Res. 2021; 38(6):1125-1137.

PMID: 34100217 DOI: 10.1007/s11095-021-03063-3.


Novel therapies for acromegaly.

Maia B, Kasuki L, Gadelha M Endocr Connect. 2021; 9(12):R274-R285.

PMID: 33434151 PMC: 7774757. DOI: 10.1530/EC-20-0433.


Assessing the Utility of In Vitro Screening Tools for Predicting Bio-Performance of Oral Peptide Delivery.

Gadgil P, Alleyne C, Feng K, Hu M, Gindy M, Buevich A Pharm Res. 2019; 36(10):151.

PMID: 31451949 DOI: 10.1007/s11095-019-2682-8.


New therapeutic agents for acromegaly.

Melmed S Nat Rev Endocrinol. 2015; 12(2):90-8.

PMID: 26610414 DOI: 10.1038/nrendo.2015.196.


References
1.
Del Pozo E . Clinical applications of somatostatin. Horm Res. 1988; 29(2-3):89-91. DOI: 10.1159/000180976. View

2.
Ganapathy V, Burckhardt G, Leibach F . Characteristics of glycylsarcosine transport in rabbit intestinal brush-border membrane vesicles. J Biol Chem. 1984; 259(14):8954-9. View

3.
Fricker G, Bruns C, MUNZER J, Briner U, Albert R, Kissel T . Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization. Gastroenterology. 1991; 100(6):1544-52. DOI: 10.1016/0016-5085(91)90651-z. View

4.
Battershill P, Clissold S . Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989; 38(5):658-702. DOI: 10.2165/00003495-198938050-00002. View

5.
Satoh O, Kudo Y, Shikata H, Yamada K, Kawasaki T . Characterization of amino-acid transport systems in guinea-pig intestinal brush-border membrane. Biochim Biophys Acta. 1989; 985(2):120-6. DOI: 10.1016/0005-2736(89)90355-6. View